⌕
Harrow · HROW · Nasdaq
Tenet 30 · Weak
Compare
$29.09−3.42%At closeTenet 30 · Weak
$29.09−1.03 (−3.42%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Harrow (HROW) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Seeking AlphaNov 16, 2026 · 02:31 ET
Harrow: Strong Revenue Growth And Operating Leverage Ahead

Harrow Inc. is positioned to achieve its ambitious $350MM 2026 revenue target after strong Q3 execution. VEVYE and IHEEZO delivered robust sequential growth, with VEVYE up 35% and IHEEZO up 62% quarter-over-quarter. Expa…

● Defense WorldNov 15, 2026 · 12:19 ET
66,773 Shares of Harrow, Inc. $HROW Bought by Drive Wealth Management LLC

Drive Wealth Management LLC acquired a new position in Harrow, Inc. (NASDAQ: HROW) during a recent quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 66,773 shares of the comp…

● GlobeNewsWireNov 12, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Harrow to Participate in Two Investor Conferences in November

NASHVILLE, Tenn., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following…

● Seeking AlphaNov 10, 2026 · 14:10 ET
Harrow, Inc. (HROW) Q3 2026 Earnings Call Transcript

Harrow, Inc. ( HROW ) Q3 2026 Earnings Call November 10, 2026 8:00 AM EST Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO, Chairman of the Board & Founder Andrew…

● MarketBeatNov 10, 2026 · 10:17 ET
Harrow Q3 Earnings Call Highlights

Harrow NASDAQ: HROW reported record third-quarter revenue and reaffirmed its full-year sales forecast, but sharply reduced its adjusted earnings outlook as lower-than-expected margins and accelerated spending weighed on …

● Zacks Investment ResearchNov 9, 2026 · 20:01 ET
Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Harrow (HROW) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the…

● Zacks Investment ResearchNov 9, 2026 · 19:36 ET
Harrow (HROW) Q3 Earnings Lag Estimates

Harrow (HROW) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.33 per share a year ago.…

● GlobeNewsWireNov 9, 2026 · 16:02 ETCOMPANY'S OWN WORDS
Harrow Announces Third Quarter 2026 Financial Results

Third Quarter 2026 and Selected Highlights: Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year Branded revenue of $83.5 million, up 62% year over year and approximately 84% of total…

● Zacks Investment ResearchNov 2, 2026 · 11:01 ET
Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?

Harrow (HROW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● Business WireNov 2, 2026 · 09:00 ET
PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow's Eye Care Portfolio

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--PHIL Inc., the technology-powered patient access platform, today announced its partnership with Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in …

● GlobeNewsWireNov 2, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Harrow Launches HarrowRx Platform

NASHVILLE, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of HarrowRx, a prescribing and access …

● Seeking AlphaOct 29, 2026 · 13:43 ET
Harrow's Top Two Drugs Alone Can Justify Its Current Valuation

Harrow trades at a 52-week low due to management miscommunication and short-term revenue volatility, but its fundamentals remain robust. Vevye and Iheezo, Harrow's flagship drugs, both address large, underpenetrated mark…

● GlobeNewsWireOct 26, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026

NASHVILLE, Tenn., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the…

● Zacks Investment ResearchOct 9, 2026 · 09:50 ET
Do Options Traders Know Something About Harrow Stock We Don't?

Investors need to pay close attention to HROW stock based on the movements in the options market lately.…

● Defense WorldOct 7, 2026 · 08:12 ET
Harrow (NASDAQ:HROW) Stock Keeps Buy Rating at BTIG Research

Harrow (NASDAQ: HROW - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at BTIG Research in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $63.00 ta…

● GlobeNewsWireOct 5, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Harrow Closes Acquisition of TYRVAYA®

First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds …

● Defense WorldSep 30, 2026 · 07:15 ET
Harrow, Inc. (NASDAQ:HROW) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated …

● GlobeNewsWireSep 30, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO

NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific abstracts featuring data from…

● Defense WorldSep 30, 2026 · 06:21 ET
Harrow (NASDAQ:HROW) Stock Falls 6.8% – Here’s Why

Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) dropped 6.8% during trading on Monday. The company traded as low as $31.64 and last traded at $30.8280. Approximately 176,792 shares were traded during trading, a d…

● Defense WorldSep 30, 2026 · 02:15 ET
Head-To-Head Contrast: Harrow (NASDAQ:HROW) & Supernus Pharmaceuticals (NASDAQ:SUPN)

Harrow (NASDAQ: HROW - Get Free Report) and Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the str…

● GlobeNewsWireSep 1, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Harrow to Participate in Three Investor Conferences in September

NASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the followin…

● BenzingaAug 21, 2026 · 12:09 ET
Harrow's Iheezo Cuts Eye-Injection Discomfort by More Than Half

Ophthalmic disease management company Harrow Inc. (NASDAQ:HROW) on Thursday shared outcomes from a prospective, randomized, contralateral-eye clinical study.…

● GlobeNewsWireAug 20, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections

Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest Patients reported approximat…

GlobeNewsWire · Nov 2, 2026

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just HROW · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.